Jennison Associates
CLDX icon

Jennison Associates’s Celldex Therapeutics CLDX Stock Holding History

Jennison Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,324,410
Closed -$45M – 591
2024
Q3 		$45M Buy
1,324,410
+321,325
+32% +$12.2M 0.03% 248
2024
Q2 		$37.1M Buy
1,003,085
+315,005
+46% +$11.9M 0.02% 260
2024
Q1 		$28.9M Buy
688,080
+668,002
+3,327% +$27.4M 0.02% 299
2023
Q4 		$796K Sell
20,078
-6,812
-25% -$200K ﹤0.01% 517
2023
Q3 		$740K Sell
26,890
-1,302,205
-98% -$40.8M ﹤0.01% 498
2023
Q2 		$45.1M Sell
1,329,095
-252,995
-16% -$8.53M 0.04% 202
2023
Q1 		$56.9M Buy
1,582,090
+26,772
+2% +$1.16M 0.05% 168
2022
Q4 		$69.3M Buy
1,555,318
+281,297
+22% +$10M 0.07% 149
2022
Q3 		$35.8M Buy
+1,274,021
New +$39.1M 0.04% 226
2014
Q4 		– Sell
-201,845
Closed -$39.2M – 727
2014
Q3 		$39.2M Sell
201,845
-10,312
-5% -$2.25M 0.04% 363
2014
Q2 		$51.9M Sell
212,157
-20,398
-9% -$4.61M 0.05% 322
2014
Q1 		$61.6M Sell
232,555
-32,899
-12% -$12.6M 0.06% 292
2013
Q4 		$96.4M Sell
265,454
-19,404
-7% -$7.48M 0.09% 197
2013
Q3 		$151M Sell
284,858
-26,645
-9% -$9.14M 0.16% 132
2013
Q2 		$72.9M Buy
+311,503
New +$61.3M 0.08% 230

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jennison Associates's CLDX Position: Q4 2024 in Review

Jennison Associates sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 1,324,410 shares — an estimated $45M sold.

Jennison Associates first reported a position in CLDX in Q2 2013 and held it in 15 quarters. The position peaked at $151M in Q3 2013. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Jennison Associates reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jennison Associates sold 1,324,410 Celldex Therapeutics shares in Q4 2024, an estimated $45M.
  • Jennison Associates first reported a position in Celldex Therapeutics in Q2 2013 and held it in 15 quarters.
  • Jennison Associates's Celldex Therapeutics position peaked at $151M in Q3 2013.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Jennison Associates's 13F filing for Q4 2024, filed 24 Jan 2025.